Cwm LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Cwm LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 0.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,404,722 shares of the biopharmaceutical company’s stock after acquiring an additional 5,059 shares during the quarter. Cwm LLC’s holdings in Pfizer were worth $35,596,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares during the period. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter worth $2,328,986,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Pfizer by 7.7% during the 4th quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after buying an additional 4,167,222 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5%

Shares of Pfizer stock opened at $25.65 on Friday. The business has a 50-day moving average of $23.89 and a 200-day moving average of $24.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The company has a market capitalization of $145.83 billion, a PE ratio of 18.59, a P/E/G ratio of 0.94 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company’s revenue was down 7.8% on a year-over-year basis. During the same period last year, the firm earned $0.82 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. Pfizer’s payout ratio is 124.64%.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Leerink Partners dropped their price objective on Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a report on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup upped their price objective on Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.